Exelixis Inc (EXEL) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Oct 02 2026 to Oct 03 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Exelixis Inc   (NASDAQ: EXEL)


Exelixis Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Exelixis Inc's ROI in the third quarter of 2026?
Exelixis Inc achieved a return on average invested assets (ROI) of 75.01 % in its third quarter of 2026, this is above EXEL's average return on investment of 5.27%.
Exelixis Inc s investments during the 12 months ending in the third quarter of 2026 are valued at $2 billion

ROI decreased relative to the period ending Jul 03 2026, due to the decline in net income.

Within the Healthcare sector 16 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 15 to 55.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Oct 02 2026)
III. Quarter		 (Jul 03 2026)
II. Quarter		 (Apr 03 2026)
I. Quarter		 (Jan 02 2026)
IV. Quarter		 (Oct 03 2025)
III. Quarter
Y / Y Investment Change TTM -8.99 % -6.54 % -5.24 % -3 % -1.99 %
Y / Y Net Income Change TTM 7.54 % 37.6 % 90.78 % 188.56 % 468.77 %
Investment (TTM) in Millions 2,102 2,132 2,223 2,439 2,450
Return On Investment (TTM) 75.01 % 82.05 % 77.71 % 71.31 % 63.48 %
EXEL's Overall Ranking # 55 # 15 # 10 # 6 #
Seq. Investment Change TTM -3.77 % -2.22 % -2.23 % -1.08 % -1.17 %
Seq. Net Income Change TTM -12.02 % 3.24 % 6.55 % 11.13 % 12.57 %
Net Income (TTM) in Millions 1,668 1,896 1,837 1,724 1,551

EXEL Company Profile >> Back to EXEL Roi Comparisons >> See Annual EXEL Return On Investment



Return On Investment EXEL's Ranking
Within: No.
Industry # 4
Sector # 17
Overall # 55

Return On Investment Statistics
High Average Low
82.05 %
5.27 %
-105.94 %
(Jul 03 2026)   (Apr 03 2015)







Financial Statements
Exelixis Inc's III. Quarter Investments $ 2,102 Millions EXEL's Balance sheet
Exelixis Inc's III. Quarter Income $ 218 Millions Quarterly EXEL's Income Statement
EXEL's Income by Division See EXEL's Income by Division


EXEL Annual Return On Investment (Jan 02 2026)
2025		 (Jan 03 2025)
2024		 (Dec 29 2023)
2023		 (Dec 30 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 2,439 2,544 2,548 2,747 2,279
Y / Y Investment Growth -4.13 % -0.16 % -7.25 % 20.56 % 17.9 %
Net Income in Millions 1,724 1,203 465 417 525
Y / Y Net Income Growth 43.3 % 158.53 % 11.68 % -20.67 % 369.86 %
Annual Return On Investment 70.68 % 47.29 % 18.26 % 15.17 % 23.05 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 70.68 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
EXEL's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for EXEL's Competitors
Subscribers only: Roi for Exelixis Inc's Suppliers
Subscribers only: Return On Investment for EXEL's Customers

Other Ratios
EXEL's Roa EXEL's Inventory Turnover Ratio EXEL's Growth Rates EXEL's Dividend Statistics
EXEL's Profitability Ratios EXEL's Asset Turnover Ratio EXEL's Dividend Growth
EXEL's Roe EXEL's Valuation Ratios EXEL's Financial Strength Ratios EXEL's Dividend Payout Ratio



Companies with similar Return On Investment at Oct 02 2026, within Healthcare Sector ROI
Indivior Pharmaceuticals Inc   108.22 %
Exelixis Inc   75.01 %
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %

Date modified: 2026-10-30T16:59:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.